510(k) Report

510(k) · Cleared

Cleared

Bard Composite Prosthesis

K971745510(k) TraditionalCleared Aug 6, 199786-day reviewClass II21 CFR 878.3300

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Davol Inc., Sub. C. R. Bard, Inc. · FTL Mesh, Surgical, Polymeric

Cleared on Aug 6, 1997 after an 86-day review. The FDA summary names its predicate without a number. 38 later devices descend from it.

Decided
Aug 6, 1997
Review
86 days
Class
Class II
Product code
FTL
Recalls
None
Predicates
0

38 later devices descend from it, 3 citing it directly.

Descendants, by year cleared 2008: 3 descendants cleared2000: 1 descendant cleared2007: 2 descendants cleared2004: 1 descendant cleared2005: 1 descendant cleared2011: 3 descendants cleared2006: 1 descendant cleared2010: 1 descendant cleared2014: 4 descendants cleared2012: 2 descendants cleared2013: 2 descendants cleared2015: 3 descendants cleared2019: 3 descendants cleared2025: 1 descendant cleared2018: 4 descendants cleared2016: 1 descendant cleared2017: 2 descendants cleared2022: 1 descendant cleared2021: 1 descendant cleared2020: 1 descendant cleared1995200020052010201520202025
  1. This deviceK971745 Bard Composite ProsthesisDavol Inc., Sub. C. R. Bard, Inc. · 1997
  2. Descendant · cites it directly · 35 of its ownK994328 Sepramesh Biosurgical Composite, Model SMBC-XXXGenzyme Corp. · 2000
  3. Descendant · 2 generations on · 34 of its ownK040868 Sepramesh IP Bioresorbable Barrier - Permanent MeshGenzyme Corp. · 2004
  4. Descendant · 2 generations on · 17 of its ownK053066 Sepramesh IP Bioresorbable Coating/Permanent MeshGenzyme Corporation · 2005
  5. Descendant · 3 generations on · 16 of its ownK063739 Sepramesh, Model 5959-1214Genzyme Corporation · 2007
  6. Descendant · 3 generations on · 15 of its ownK062915 Veritas Collagen MatrixSynovis Surgical Innovations · 2006 · Recalled

Showing 5 of 38 descendants. See all descendants

Descendants cleared per year

2000: 12004: 12005: 12006: 12007: 22008: 32010: 12011: 32012: 22013: 22014: 42015: 32016: 12017: 22018: 42019: 32020: 12021: 12022: 12025: 1
2000high 4 (2014) · low 0 (2001)2026

Most influential descendants

Showing 5 of 38 · See all
  • K994328Sepramesh Biosurgical Composite, Model SMBC-XXXGenzyme Corp. · 2000 · cites it directly35descendants
  • K040868Sepramesh IP Bioresorbable Barrier - Permanent MeshGenzyme Corp. · 2004 · 2 generations on34descendants
  • K053066Sepramesh IP Bioresorbable Coating/Permanent MeshGenzyme Corporation · 2005 · 2 generations on17descendants
  • K063739Sepramesh, Model 5959-1214Genzyme Corporation · 2007 · 3 generations on16descendants
  • K062915Veritas Collagen MatrixSynovis Surgical Innovations · 2006 · 3 generations on15descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)K971745Bard Composite ProsthesisDavol Inc., Sub. C. R. Bard, Inc.1997—
+1K994328Sepramesh Biosurgical Composite, Model SMBC-XXXGenzyme Corp.2000—
+2K040868Sepramesh IP Bioresorbable Barrier - Permanent MeshGenzyme Corp.2004—
+2K053066Sepramesh IP Bioresorbable Coating/Permanent MeshGenzyme Corporation2005—
+3K063739Sepramesh, Model 5959-1214Genzyme Corporation2007—
+3K062915Veritas Collagen MatrixSynovis Surgical Innovations20061

Descendants by year cleared

Year clearedDevicesWith a Class I recall
200010
200410
200510
200610
200720
200830
201010
201130
201220
201320
201440
201530
201610
201720
201840
201930
202010
202110
202210
202510
FIG. 1 — Lineage of K971745, 1997–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in FTL? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new FTL device

  1. #1 K220091 Poly-Tape/Infinity-Lock Soft Tissue…score 16.8 · 14 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*—Bard Marlex Mesh
Named without a submission number
—
*—GORE-TEX Dual Mesh
Named without a submission number
—

What descends from it? (38)

See all 38

3 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K994328Sepramesh Biosurgical Composite, Model SMBC-XXXGenzyme Corp.200035
K081327RelimeshHerniamesh S.R.L.20080
K063154Facial Reconstructive Mesh (FRM)Evera Medical, Inc.20070

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K994328 (Genzyme Corp., 2000) has gone furthest, with 35 descendants of its own.

How does its category compare?

All FTL devices

FTL Mesh, Surgical, Polymeric: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · FTL

6in 2025

2007: 202008: 232009: 152010: 182011: 152012: 122013: 82014: 112015: 122016: 32017: 62018: 122019: 42020: 52021: 22022: 62023: 42024: 22025: 62026 (partial year): 2
2007high 23 (2008) · low 2 (2021)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · FTL

30in 2025

2007: 92 days median2008: 114 days median2009: 97 days median2010: 132 days median2011: 90 days median2012: 213 days median2013: 90 days median2014: 70 days median2015: 121 days median2016: 186 days median2017: 132 days median2018: 105 days median2019: 99 days median2020: 138 days median2022: 195 days median2023: 29 days median2025: 30 days median
2007high 213 (2012) · low 29 (2023)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · FTL

1in 2020

2007: 22008: 12009: 12010: 122011: 82012: 22013: 12014: 32017: 12018: 12020: 1
2007high 12 (2010) · low 0 (2015)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · FTL

3,487in 2025

2007: 1,7372008: 1,5692009: 1,9062010: 2,1752011: 3,6082012: 14,7002013: 26,5192014: 2,6832015: 2,5262016: 2,4172017: 3,9472018: 11,8932019: 21,7242020: 18,8192021: 16,2842022: 11,4392023: 8,0252024: 8,5652025: 3,487
2007high 26,519 (2013) · low 1,569 (2008)2025

MAUDE reports naming product code FTL, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007209221,737
20082311411,569
2009159711,906
201018132122,175
2011159083,608
201212213214,700
2013890126,519
2014117032,683
20151212102,526
2016318602,417
2017613213,947
201812105111,893
2019499021,724
20205138118,819
20212—016,284
20226195011,439
202342908,025
20242—08,565
202563003,487
20262—0—

What is it indicated for?

Reconstruction of soft tissue deficiencies, such as for the repair of hernias and chest wall defects.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K971745: Bard Composite Prosthesis.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K971745

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026